Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes Journal Article

  


Authors: O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Gerecitano, J.; Gonen, M.; Dumitrescu, O.; Sarasohn, D.; Butos, J.; Neylon, E.; Cortelli, B. M. G.; Blumel, S.; Evens, A. M.; Zelenetz, A. D.; Wright, J.; Cooper, B.; Winter, J.; Vose, J.
Article Title: Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
Abstract: Purpose: To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma. Experimental Design: Patients with follicular lymphoma (FL), marginal zone lymphoma, mantle cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia were eligible for study. Bortezomib was given at a dose of 1.5 mg/m2 as an i.v. push on days 1, 4, 8, and 11 of a 21-day cycle. Eligibility included the following: (a) no more than three prior therapies, (b) at least 1 month since prior chemotherapy, (c) measurable disease, and (d) an absolute neutrophil count of >1,000/μL and a platelet count >50,000/μL for the first dose of any cycle. Results: Seventy-seven patients were registered, of which 69 were assessable for response based on the completion of two cycles of therapy. Subtypes included FL (59.5%), mantle cell lymphoma (52%), small lymphocytic lymphoma/chronic lymphocytic leukemia (16.2%), marginal zone lymphoma (21.6%), and one Waldenstrom's macroglobulinemia. The median number of prior therapies was three. Themost common grade 3 toxicity was lymphopenia (35%) and thrombocytopenia (31%). Twenty-five patients experienced grade ≤2 sensory neuropathy (32), and 8% experienced grade 3 neurosensory toxicity. The overall response rate was 45% (40% on an intention to treat) including 10 complete remissions. Of 18 patients with FL, 9 responded with 4 complete response. The median time to treatment response for FL was 12 weeks, whereas the median time to treatment response for other subtypes of non-Hodgkin's lymphoma was only 4 weeks. Conclusions: These data suggest that bortezomib has significant single agent activity in patients with FL, and that longer durations of treatment may improve overall response. ©2010 AACR.
Keywords: adult; cancer survival; clinical article; controlled study; treatment outcome; aged; aged, 80 and over; disease-free survival; middle aged; survival analysis; clinical trial; constipation; fatigue; diarrhea; drug dose reduction; monotherapy; side effect; treatment duration; progression free survival; bortezomib; controlled clinical trial; drug eruption; mantle cell lymphoma; multiple cycle treatment; neutrophil count; phase 2 clinical trial; sensory neuropathy; thrombocyte; boronic acids; pyrazines; anemia; nausea; thrombocytopenia; recurrence; aciclovir; creatinine; herpes zoster; waldenstroem macroglobulinemia; antineoplastic activity; time factors; asthenia; coughing; hyperglycemia; lymphocytopenia; alanine aminotransferase; alkaline phosphatase; aspartate aminotransferase; bilirubin; chemotherapy induced emesis; hyperkalemia; hypoalbuminemia; hypokalemia; lymphoma, b-cell; cancer regression; neutrophil; disease progression; multicenter study; drug response; thrombocyte count; hypoglycemia; chronic lymphatic leukemia; neuropathic pain; follicular lymphoma; marginal zone lymphoma; lymphoma, follicular; leukocyte; lymphocytoma; hypernatremia; hypocalcemia; opportunistic infection
Journal Title: Clinical Cancer Research
Volume: 16
Issue: 2
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2010-01-15
Start Page: 719
End Page: 726
Language: English
DOI: 10.1158/1078-0432.ccr-08-2647
PUBMED: 20068103
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-74549164108&partnerID=40&md5=c4d5d9dbf5a16e623729ad387fc3d8f8
Notes: --- - "Cited By (since 1996): 4" - "Export Date: 20 April 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Carol Portlock
    206 Portlock
  2. Craig Moskowitz
    407 Moskowitz
  3. Mithat Gonen
    1037 Gonen
  4. Debra Marion Sarasohn
    48 Sarasohn
  5. John Frank Gerecitano
    153 Gerecitano
  6. Otilia-Liana Dumitrescu
    14 Dumitrescu
  7. Andrew D Zelenetz
    784 Zelenetz
  8. Paul Hamlin
    293 Hamlin
  9. David J Straus
    361 Straus
  10. John N Butos
    5 Butos
Related MSK Work